nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—P-Glycoprotein Inhibitors—Cyclosporine—systemic lupus erythematosus	0.544	1	CiPCiCtD
Vemurafenib—ALB—systemic lupus erythematosus	0.103	1	CbGaD
Vemurafenib—ABCG2—Leflunomide—systemic lupus erythematosus	0.0334	0.142	CbGbCtD
Vemurafenib—ABCC1—Cyclosporine—systemic lupus erythematosus	0.0233	0.0995	CbGbCtD
Vemurafenib—ABCG2—Mycophenolate mofetil—systemic lupus erythematosus	0.0206	0.0879	CbGbCtD
Vemurafenib—ABCG2—Hydrocortisone—systemic lupus erythematosus	0.0165	0.0705	CbGbCtD
Vemurafenib—ABCG2—Cyclosporine—systemic lupus erythematosus	0.0156	0.0666	CbGbCtD
Vemurafenib—ALB—Mycophenolate mofetil—systemic lupus erythematosus	0.0142	0.0606	CbGbCtD
Vemurafenib—CYP1A2—Leflunomide—systemic lupus erythematosus	0.0138	0.0587	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—systemic lupus erythematosus	0.0124	0.0527	CbGbCtD
Vemurafenib—ALB—Prednisone—systemic lupus erythematosus	0.0114	0.0484	CbGbCtD
Vemurafenib—ABCG2—Dexamethasone—systemic lupus erythematosus	0.0103	0.0439	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—systemic lupus erythematosus	0.00827	0.0353	CbGbCtD
Vemurafenib—CYP3A4—Methylprednisolone—systemic lupus erythematosus	0.00588	0.0251	CbGbCtD
Vemurafenib—ALB—Methotrexate—systemic lupus erythematosus	0.0057	0.0243	CbGbCtD
Vemurafenib—CYP2D6—Cyclosporine—systemic lupus erythematosus	0.00531	0.0226	CbGbCtD
Vemurafenib—CYP3A4—Dapsone—systemic lupus erythematosus	0.00514	0.0219	CbGbCtD
Vemurafenib—CYP3A4—Mycophenolate mofetil—systemic lupus erythematosus	0.00445	0.019	CbGbCtD
Vemurafenib—CYP3A4—Triamcinolone—systemic lupus erythematosus	0.00445	0.019	CbGbCtD
Vemurafenib—CYP3A4—Betamethasone—systemic lupus erythematosus	0.00382	0.0163	CbGbCtD
Vemurafenib—CYP3A4—Prednisolone—systemic lupus erythematosus	0.00377	0.0161	CbGbCtD
Vemurafenib—CYP3A4—Hydrocortisone—systemic lupus erythematosus	0.00357	0.0152	CbGbCtD
Vemurafenib—CYP3A4—Prednisone—systemic lupus erythematosus	0.00356	0.0152	CbGbCtD
Vemurafenib—CYP2D6—Dexamethasone—systemic lupus erythematosus	0.0035	0.0149	CbGbCtD
Vemurafenib—CYP3A4—Cyclosporine—systemic lupus erythematosus	0.00338	0.0144	CbGbCtD
Vemurafenib—CYP3A4—Dexamethasone—systemic lupus erythematosus	0.00222	0.00948	CbGbCtD
Vemurafenib—CYP1A2—urine—systemic lupus erythematosus	0.00095	0.0665	CbGeAlD
Vemurafenib—CYP3A4—urine—systemic lupus erythematosus	0.000688	0.0481	CbGeAlD
Vemurafenib—BRAF—tendon—systemic lupus erythematosus	0.000684	0.0479	CbGeAlD
Vemurafenib—CYP2D6—urine—systemic lupus erythematosus	0.000677	0.0473	CbGeAlD
Vemurafenib—RAF1—connective tissue—systemic lupus erythematosus	0.000663	0.0464	CbGeAlD
Vemurafenib—BRAF—bone marrow—systemic lupus erythematosus	0.000663	0.0464	CbGeAlD
Vemurafenib—RAF1—nephron tubule—systemic lupus erythematosus	0.000643	0.0449	CbGeAlD
Vemurafenib—BRAF—lung—systemic lupus erythematosus	0.000601	0.042	CbGeAlD
Vemurafenib—RAF1—skin of body—systemic lupus erythematosus	0.000599	0.0419	CbGeAlD
Vemurafenib—RAF1—kidney—systemic lupus erythematosus	0.000565	0.0395	CbGeAlD
Vemurafenib—RAF1—cortex of kidney—systemic lupus erythematosus	0.00055	0.0385	CbGeAlD
Vemurafenib—CYP1A2—blood plasma—systemic lupus erythematosus	0.000496	0.0347	CbGeAlD
Vemurafenib—RAF1—lymphoid tissue—systemic lupus erythematosus	0.000485	0.0339	CbGeAlD
Vemurafenib—Etoricoxib—PTGS2—systemic lupus erythematosus	0.000476	1	CrCbGaD
Vemurafenib—RAF1—tendon—systemic lupus erythematosus	0.000456	0.0319	CbGeAlD
Vemurafenib—RAF1—bone marrow—systemic lupus erythematosus	0.000442	0.0309	CbGeAlD
Vemurafenib—RAF1—lung—systemic lupus erythematosus	0.0004	0.028	CbGeAlD
Vemurafenib—RAF1—nervous system—systemic lupus erythematosus	0.000371	0.0259	CbGeAlD
Vemurafenib—CYP3A4—blood plasma—systemic lupus erythematosus	0.000359	0.0251	CbGeAlD
Vemurafenib—RAF1—central nervous system—systemic lupus erythematosus	0.000357	0.025	CbGeAlD
Vemurafenib—CYP2D6—blood plasma—systemic lupus erythematosus	0.000353	0.0247	CbGeAlD
Vemurafenib—ORM1—bone marrow—systemic lupus erythematosus	0.000305	0.0213	CbGeAlD
Vemurafenib—ORM1—lung—systemic lupus erythematosus	0.000276	0.0193	CbGeAlD
Vemurafenib—ABCC1—cortex of kidney—systemic lupus erythematosus	0.000275	0.0192	CbGeAlD
Vemurafenib—ABCG2—nephron tubule—systemic lupus erythematosus	0.000266	0.0186	CbGeAlD
Vemurafenib—ORM1—nervous system—systemic lupus erythematosus	0.000256	0.0179	CbGeAlD
Vemurafenib—ORM1—central nervous system—systemic lupus erythematosus	0.000246	0.0172	CbGeAlD
Vemurafenib—ABCC1—tendon—systemic lupus erythematosus	0.000228	0.0159	CbGeAlD
Vemurafenib—ABCC1—lung—systemic lupus erythematosus	0.0002	0.014	CbGeAlD
Vemurafenib—ABCG2—bone marrow—systemic lupus erythematosus	0.000183	0.0128	CbGeAlD
Vemurafenib—ABCG2—lung—systemic lupus erythematosus	0.000166	0.0116	CbGeAlD
Vemurafenib—CYP3A4—kidney—systemic lupus erythematosus	0.000163	0.0114	CbGeAlD
Vemurafenib—CYP2D6—kidney—systemic lupus erythematosus	0.00016	0.0112	CbGeAlD
Vemurafenib—CYP1A2—lung—systemic lupus erythematosus	0.000159	0.0111	CbGeAlD
Vemurafenib—CYP3A4—nervous system—systemic lupus erythematosus	0.000107	0.00747	CbGeAlD
Vemurafenib—CYP2D6—nervous system—systemic lupus erythematosus	0.000105	0.00735	CbGeAlD
Vemurafenib—CYP3A4—central nervous system—systemic lupus erythematosus	0.000103	0.00719	CbGeAlD
Vemurafenib—CYP2D6—central nervous system—systemic lupus erythematosus	0.000101	0.00707	CbGeAlD
Vemurafenib—Cough—Mycophenolate mofetil—systemic lupus erythematosus	9.13e-05	0.00167	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—systemic lupus erythematosus	9.07e-05	0.00166	CcSEcCtD
Vemurafenib—Erythema—Triamcinolone—systemic lupus erythematosus	8.98e-05	0.00164	CcSEcCtD
Vemurafenib—Body temperature increased—Leflunomide—systemic lupus erythematosus	8.97e-05	0.00164	CcSEcCtD
Vemurafenib—Malnutrition—Methylprednisolone—systemic lupus erythematosus	8.96e-05	0.00164	CcSEcCtD
Vemurafenib—Erythema—Methylprednisolone—systemic lupus erythematosus	8.96e-05	0.00164	CcSEcCtD
Vemurafenib—Arthralgia—Mycophenolate mofetil—systemic lupus erythematosus	8.91e-05	0.00163	CcSEcCtD
Vemurafenib—Myalgia—Mycophenolate mofetil—systemic lupus erythematosus	8.91e-05	0.00163	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Prednisone—systemic lupus erythematosus	8.9e-05	0.00163	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Methotrexate—systemic lupus erythematosus	8.86e-05	0.00162	CcSEcCtD
Vemurafenib—Hypersensitivity—Azathioprine—systemic lupus erythematosus	8.85e-05	0.00162	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic lupus erythematosus	8.85e-05	0.00162	CcSEcCtD
Vemurafenib—Dysgeusia—Triamcinolone—systemic lupus erythematosus	8.79e-05	0.00161	CcSEcCtD
Vemurafenib—Anaphylactic shock—Cyclosporine—systemic lupus erythematosus	8.76e-05	0.0016	CcSEcCtD
Vemurafenib—Eye disorder—Dexamethasone—systemic lupus erythematosus	8.74e-05	0.0016	CcSEcCtD
Vemurafenib—Eye disorder—Betamethasone—systemic lupus erythematosus	8.74e-05	0.0016	CcSEcCtD
Vemurafenib—Infection—Cyclosporine—systemic lupus erythematosus	8.7e-05	0.00159	CcSEcCtD
Vemurafenib—Back pain—Triamcinolone—systemic lupus erythematosus	8.68e-05	0.00159	CcSEcCtD
Vemurafenib—Nervous system disorder—Cyclosporine—systemic lupus erythematosus	8.59e-05	0.00157	CcSEcCtD
Vemurafenib—Anaphylactic shock—Mycophenolate mofetil—systemic lupus erythematosus	8.54e-05	0.00156	CcSEcCtD
Vemurafenib—Skin disorder—Cyclosporine—systemic lupus erythematosus	8.5e-05	0.00156	CcSEcCtD
Vemurafenib—Angiopathy—Dexamethasone—systemic lupus erythematosus	8.49e-05	0.00155	CcSEcCtD
Vemurafenib—Angiopathy—Betamethasone—systemic lupus erythematosus	8.49e-05	0.00155	CcSEcCtD
Vemurafenib—Infection—Mycophenolate mofetil—systemic lupus erythematosus	8.48e-05	0.00155	CcSEcCtD
Vemurafenib—Eosinophilia—Methotrexate—systemic lupus erythematosus	8.42e-05	0.00154	CcSEcCtD
Vemurafenib—Nervous system disorder—Mycophenolate mofetil—systemic lupus erythematosus	8.38e-05	0.00153	CcSEcCtD
Vemurafenib—Hypersensitivity—Leflunomide—systemic lupus erythematosus	8.36e-05	0.00153	CcSEcCtD
Vemurafenib—Skin disorder—Mycophenolate mofetil—systemic lupus erythematosus	8.3e-05	0.00152	CcSEcCtD
Vemurafenib—Alopecia—Dexamethasone—systemic lupus erythematosus	8.27e-05	0.00151	CcSEcCtD
Vemurafenib—Alopecia—Betamethasone—systemic lupus erythematosus	8.27e-05	0.00151	CcSEcCtD
Vemurafenib—Diarrhoea—Azathioprine—systemic lupus erythematosus	8.22e-05	0.0015	CcSEcCtD
Vemurafenib—Erythema—Dexamethasone—systemic lupus erythematosus	8.15e-05	0.00149	CcSEcCtD
Vemurafenib—Erythema—Betamethasone—systemic lupus erythematosus	8.15e-05	0.00149	CcSEcCtD
Vemurafenib—Asthenia—Leflunomide—systemic lupus erythematosus	8.14e-05	0.00149	CcSEcCtD
Vemurafenib—Myalgia—Hydrocortisone—systemic lupus erythematosus	8.12e-05	0.00148	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—systemic lupus erythematosus	8.06e-05	0.00147	CcSEcCtD
Vemurafenib—Pruritus—Leflunomide—systemic lupus erythematosus	8.03e-05	0.00147	CcSEcCtD
Vemurafenib—Connective tissue disorder—Prednisone—systemic lupus erythematosus	8.01e-05	0.00146	CcSEcCtD
Vemurafenib—Hypotension—Mycophenolate mofetil—systemic lupus erythematosus	7.98e-05	0.00146	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Cyclosporine—systemic lupus erythematosus	7.98e-05	0.00146	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisolone—systemic lupus erythematosus	7.97e-05	0.00146	CcSEcCtD
Vemurafenib—Dizziness—Azathioprine—systemic lupus erythematosus	7.94e-05	0.00145	CcSEcCtD
Vemurafenib—Cough—Triamcinolone—systemic lupus erythematosus	7.83e-05	0.00143	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic lupus erythematosus	7.78e-05	0.00142	CcSEcCtD
Vemurafenib—Anaphylactic shock—Hydrocortisone—systemic lupus erythematosus	7.78e-05	0.00142	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Methotrexate—systemic lupus erythematosus	7.77e-05	0.00142	CcSEcCtD
Vemurafenib—Diarrhoea—Leflunomide—systemic lupus erythematosus	7.76e-05	0.00142	CcSEcCtD
Vemurafenib—Infection—Hydrocortisone—systemic lupus erythematosus	7.73e-05	0.00141	CcSEcCtD
Vemurafenib—Myalgia—Triamcinolone—systemic lupus erythematosus	7.64e-05	0.0014	CcSEcCtD
Vemurafenib—Vomiting—Azathioprine—systemic lupus erythematosus	7.64e-05	0.0014	CcSEcCtD
Vemurafenib—Nervous system disorder—Hydrocortisone—systemic lupus erythematosus	7.63e-05	0.0014	CcSEcCtD
Vemurafenib—Arthralgia—Methylprednisolone—systemic lupus erythematosus	7.63e-05	0.00139	CcSEcCtD
Vemurafenib—Myalgia—Methylprednisolone—systemic lupus erythematosus	7.63e-05	0.00139	CcSEcCtD
Vemurafenib—Eye disorder—Prednisone—systemic lupus erythematosus	7.62e-05	0.00139	CcSEcCtD
Vemurafenib—Decreased appetite—Cyclosporine—systemic lupus erythematosus	7.61e-05	0.00139	CcSEcCtD
Vemurafenib—Infestation NOS—Methotrexate—systemic lupus erythematosus	7.59e-05	0.00139	CcSEcCtD
Vemurafenib—Infestation—Methotrexate—systemic lupus erythematosus	7.59e-05	0.00139	CcSEcCtD
Vemurafenib—Rash—Azathioprine—systemic lupus erythematosus	7.57e-05	0.00139	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—systemic lupus erythematosus	7.57e-05	0.00139	CcSEcCtD
Vemurafenib—Dermatitis—Azathioprine—systemic lupus erythematosus	7.57e-05	0.00138	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Cyclosporine—systemic lupus erythematosus	7.56e-05	0.00138	CcSEcCtD
Vemurafenib—Skin disorder—Hydrocortisone—systemic lupus erythematosus	7.56e-05	0.00138	CcSEcCtD
Vemurafenib—Fatigue—Cyclosporine—systemic lupus erythematosus	7.55e-05	0.00138	CcSEcCtD
Vemurafenib—Headache—Azathioprine—systemic lupus erythematosus	7.53e-05	0.00138	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Methotrexate—systemic lupus erythematosus	7.52e-05	0.00138	CcSEcCtD
Vemurafenib—Dizziness—Leflunomide—systemic lupus erythematosus	7.5e-05	0.00137	CcSEcCtD
Vemurafenib—Constipation—Cyclosporine—systemic lupus erythematosus	7.49e-05	0.00137	CcSEcCtD
Vemurafenib—Decreased appetite—Mycophenolate mofetil—systemic lupus erythematosus	7.42e-05	0.00136	CcSEcCtD
Vemurafenib—Angiopathy—Prednisone—systemic lupus erythematosus	7.39e-05	0.00135	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Mycophenolate mofetil—systemic lupus erythematosus	7.37e-05	0.00135	CcSEcCtD
Vemurafenib—Anaphylactic shock—Triamcinolone—systemic lupus erythematosus	7.33e-05	0.00134	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methylprednisolone—systemic lupus erythematosus	7.31e-05	0.00134	CcSEcCtD
Vemurafenib—Constipation—Mycophenolate mofetil—systemic lupus erythematosus	7.3e-05	0.00134	CcSEcCtD
Vemurafenib—Infection—Triamcinolone—systemic lupus erythematosus	7.28e-05	0.00133	CcSEcCtD
Vemurafenib—Hypotension—Hydrocortisone—systemic lupus erythematosus	7.27e-05	0.00133	CcSEcCtD
Vemurafenib—Infection—Methylprednisolone—systemic lupus erythematosus	7.26e-05	0.00133	CcSEcCtD
Vemurafenib—Vomiting—Leflunomide—systemic lupus erythematosus	7.21e-05	0.00132	CcSEcCtD
Vemurafenib—Alopecia—Prednisone—systemic lupus erythematosus	7.2e-05	0.00132	CcSEcCtD
Vemurafenib—Nervous system disorder—Methylprednisolone—systemic lupus erythematosus	7.17e-05	0.00131	CcSEcCtD
Vemurafenib—Rash—Leflunomide—systemic lupus erythematosus	7.15e-05	0.00131	CcSEcCtD
Vemurafenib—Dermatitis—Leflunomide—systemic lupus erythematosus	7.15e-05	0.00131	CcSEcCtD
Vemurafenib—Nausea—Azathioprine—systemic lupus erythematosus	7.14e-05	0.00131	CcSEcCtD
Vemurafenib—Headache—Leflunomide—systemic lupus erythematosus	7.11e-05	0.0013	CcSEcCtD
Vemurafenib—Skin disorder—Methylprednisolone—systemic lupus erythematosus	7.1e-05	0.0013	CcSEcCtD
Vemurafenib—Malnutrition—Prednisone—systemic lupus erythematosus	7.09e-05	0.0013	CcSEcCtD
Vemurafenib—Erythema—Prednisone—systemic lupus erythematosus	7.09e-05	0.0013	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Hydrocortisone—systemic lupus erythematosus	7.09e-05	0.0013	CcSEcCtD
Vemurafenib—Myalgia—Dexamethasone—systemic lupus erythematosus	6.93e-05	0.00127	CcSEcCtD
Vemurafenib—Myalgia—Betamethasone—systemic lupus erythematosus	6.93e-05	0.00127	CcSEcCtD
Vemurafenib—Body temperature increased—Cyclosporine—systemic lupus erythematosus	6.92e-05	0.00127	CcSEcCtD
Vemurafenib—Hypotension—Methylprednisolone—systemic lupus erythematosus	6.83e-05	0.00125	CcSEcCtD
Vemurafenib—Decreased appetite—Hydrocortisone—systemic lupus erythematosus	6.76e-05	0.00124	CcSEcCtD
Vemurafenib—Body temperature increased—Mycophenolate mofetil—systemic lupus erythematosus	6.75e-05	0.00123	CcSEcCtD
Vemurafenib—Nausea—Leflunomide—systemic lupus erythematosus	6.74e-05	0.00123	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	6.72e-05	0.00123	CcSEcCtD
Vemurafenib—Fatigue—Hydrocortisone—systemic lupus erythematosus	6.71e-05	0.00123	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	6.67e-05	0.00122	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	6.66e-05	0.00122	CcSEcCtD
Vemurafenib—Anaphylactic shock—Dexamethasone—systemic lupus erythematosus	6.65e-05	0.00122	CcSEcCtD
Vemurafenib—Anaphylactic shock—Betamethasone—systemic lupus erythematosus	6.65e-05	0.00122	CcSEcCtD
Vemurafenib—Infection—Betamethasone—systemic lupus erythematosus	6.6e-05	0.00121	CcSEcCtD
Vemurafenib—Infection—Dexamethasone—systemic lupus erythematosus	6.6e-05	0.00121	CcSEcCtD
Vemurafenib—Nervous system disorder—Betamethasone—systemic lupus erythematosus	6.52e-05	0.00119	CcSEcCtD
Vemurafenib—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	6.52e-05	0.00119	CcSEcCtD
Vemurafenib—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	6.45e-05	0.00118	CcSEcCtD
Vemurafenib—Erythema multiforme—Methotrexate—systemic lupus erythematosus	6.44e-05	0.00118	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—systemic lupus erythematosus	6.36e-05	0.00116	CcSEcCtD
Vemurafenib—Cardiac disorder—Methotrexate—systemic lupus erythematosus	6.32e-05	0.00116	CcSEcCtD
Vemurafenib—Fatigue—Triamcinolone—systemic lupus erythematosus	6.32e-05	0.00116	CcSEcCtD
Vemurafenib—Fatigue—Methylprednisolone—systemic lupus erythematosus	6.3e-05	0.00115	CcSEcCtD
Vemurafenib—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	6.29e-05	0.00115	CcSEcCtD
Vemurafenib—Asthenia—Cyclosporine—systemic lupus erythematosus	6.28e-05	0.00115	CcSEcCtD
Vemurafenib—Hypotension—Betamethasone—systemic lupus erythematosus	6.21e-05	0.00114	CcSEcCtD
Vemurafenib—Hypotension—Dexamethasone—systemic lupus erythematosus	6.21e-05	0.00114	CcSEcCtD
Vemurafenib—Pruritus—Cyclosporine—systemic lupus erythematosus	6.19e-05	0.00113	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—systemic lupus erythematosus	6.18e-05	0.00113	CcSEcCtD
Vemurafenib—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	6.15e-05	0.00113	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	6.14e-05	0.00112	CcSEcCtD
Vemurafenib—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	6.13e-05	0.00112	CcSEcCtD
Vemurafenib—Chills—Methotrexate—systemic lupus erythematosus	6.11e-05	0.00112	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	6.06e-05	0.00111	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	6.06e-05	0.00111	CcSEcCtD
Vemurafenib—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	6.04e-05	0.00111	CcSEcCtD
Vemurafenib—Arthralgia—Prednisone—systemic lupus erythematosus	6.04e-05	0.0011	CcSEcCtD
Vemurafenib—Myalgia—Prednisone—systemic lupus erythematosus	6.04e-05	0.0011	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—systemic lupus erythematosus	6.02e-05	0.0011	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	6e-05	0.0011	CcSEcCtD
Vemurafenib—Diarrhoea—Cyclosporine—systemic lupus erythematosus	5.99e-05	0.0011	CcSEcCtD
Vemurafenib—Malnutrition—Methotrexate—systemic lupus erythematosus	5.93e-05	0.00108	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—systemic lupus erythematosus	5.93e-05	0.00108	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisolone—systemic lupus erythematosus	5.87e-05	0.00107	CcSEcCtD
Vemurafenib—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	5.84e-05	0.00107	CcSEcCtD
Vemurafenib—Dysgeusia—Methotrexate—systemic lupus erythematosus	5.81e-05	0.00106	CcSEcCtD
Vemurafenib—Body temperature increased—Triamcinolone—systemic lupus erythematosus	5.79e-05	0.00106	CcSEcCtD
Vemurafenib—Dizziness—Cyclosporine—systemic lupus erythematosus	5.79e-05	0.00106	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisone—systemic lupus erythematosus	5.79e-05	0.00106	CcSEcCtD
Vemurafenib—Decreased appetite—Dexamethasone—systemic lupus erythematosus	5.78e-05	0.00106	CcSEcCtD
Vemurafenib—Decreased appetite—Betamethasone—systemic lupus erythematosus	5.78e-05	0.00106	CcSEcCtD
Vemurafenib—Infection—Prednisone—systemic lupus erythematosus	5.75e-05	0.00105	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	5.74e-05	0.00105	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	5.74e-05	0.00105	CcSEcCtD
Vemurafenib—Back pain—Methotrexate—systemic lupus erythematosus	5.73e-05	0.00105	CcSEcCtD
Vemurafenib—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	5.73e-05	0.00105	CcSEcCtD
Vemurafenib—Fatigue—Dexamethasone—systemic lupus erythematosus	5.73e-05	0.00105	CcSEcCtD
Vemurafenib—Fatigue—Betamethasone—systemic lupus erythematosus	5.73e-05	0.00105	CcSEcCtD
Vemurafenib—Nervous system disorder—Prednisone—systemic lupus erythematosus	5.68e-05	0.00104	CcSEcCtD
Vemurafenib—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	5.65e-05	0.00103	CcSEcCtD
Vemurafenib—Skin disorder—Prednisone—systemic lupus erythematosus	5.62e-05	0.00103	CcSEcCtD
Vemurafenib—Asthenia—Hydrocortisone—systemic lupus erythematosus	5.58e-05	0.00102	CcSEcCtD
Vemurafenib—Vomiting—Cyclosporine—systemic lupus erythematosus	5.57e-05	0.00102	CcSEcCtD
Vemurafenib—Rash—Cyclosporine—systemic lupus erythematosus	5.52e-05	0.00101	CcSEcCtD
Vemurafenib—Dermatitis—Cyclosporine—systemic lupus erythematosus	5.52e-05	0.00101	CcSEcCtD
Vemurafenib—Pruritus—Hydrocortisone—systemic lupus erythematosus	5.5e-05	0.00101	CcSEcCtD
Vemurafenib—Headache—Cyclosporine—systemic lupus erythematosus	5.48e-05	0.001	CcSEcCtD
Vemurafenib—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	5.43e-05	0.000993	CcSEcCtD
Vemurafenib—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	5.4e-05	0.000987	CcSEcCtD
Vemurafenib—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	5.39e-05	0.000985	CcSEcCtD
Vemurafenib—Rash—Mycophenolate mofetil—systemic lupus erythematosus	5.38e-05	0.000985	CcSEcCtD
Vemurafenib—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	5.38e-05	0.000984	CcSEcCtD
Vemurafenib—Headache—Mycophenolate mofetil—systemic lupus erythematosus	5.35e-05	0.000979	CcSEcCtD
Vemurafenib—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	5.32e-05	0.000974	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	5.27e-05	0.000965	CcSEcCtD
Vemurafenib—Dizziness—Prednisolone—systemic lupus erythematosus	5.27e-05	0.000964	CcSEcCtD
Vemurafenib—Asthenia—Triamcinolone—systemic lupus erythematosus	5.26e-05	0.000962	CcSEcCtD
Vemurafenib—Body temperature increased—Betamethasone—systemic lupus erythematosus	5.26e-05	0.000961	CcSEcCtD
Vemurafenib—Body temperature increased—Dexamethasone—systemic lupus erythematosus	5.26e-05	0.000961	CcSEcCtD
Vemurafenib—Asthenia—Methylprednisolone—systemic lupus erythematosus	5.24e-05	0.000959	CcSEcCtD
Vemurafenib—Nausea—Cyclosporine—systemic lupus erythematosus	5.2e-05	0.000951	CcSEcCtD
Vemurafenib—Pruritus—Triamcinolone—systemic lupus erythematosus	5.18e-05	0.000948	CcSEcCtD
Vemurafenib—Cough—Methotrexate—systemic lupus erythematosus	5.17e-05	0.000946	CcSEcCtD
Vemurafenib—Pruritus—Methylprednisolone—systemic lupus erythematosus	5.17e-05	0.000946	CcSEcCtD
Vemurafenib—Dizziness—Hydrocortisone—systemic lupus erythematosus	5.15e-05	0.000941	CcSEcCtD
Vemurafenib—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	5.07e-05	0.000928	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—systemic lupus erythematosus	5.05e-05	0.000923	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—systemic lupus erythematosus	5.05e-05	0.000923	CcSEcCtD
Vemurafenib—Decreased appetite—Prednisone—systemic lupus erythematosus	5.03e-05	0.000921	CcSEcCtD
Vemurafenib—Rash—Prednisolone—systemic lupus erythematosus	5.02e-05	0.000919	CcSEcCtD
Vemurafenib—Dermatitis—Prednisolone—systemic lupus erythematosus	5.02e-05	0.000918	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	5.01e-05	0.000917	CcSEcCtD
Vemurafenib—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	5e-05	0.000915	CcSEcCtD
Vemurafenib—Fatigue—Prednisone—systemic lupus erythematosus	4.99e-05	0.000913	CcSEcCtD
Vemurafenib—Headache—Prednisolone—systemic lupus erythematosus	4.99e-05	0.000913	CcSEcCtD
Vemurafenib—Constipation—Prednisone—systemic lupus erythematosus	4.95e-05	0.000906	CcSEcCtD
Vemurafenib—Vomiting—Hydrocortisone—systemic lupus erythematosus	4.95e-05	0.000905	CcSEcCtD
Vemurafenib—Rash—Hydrocortisone—systemic lupus erythematosus	4.91e-05	0.000897	CcSEcCtD
Vemurafenib—Dermatitis—Hydrocortisone—systemic lupus erythematosus	4.9e-05	0.000897	CcSEcCtD
Vemurafenib—Headache—Hydrocortisone—systemic lupus erythematosus	4.87e-05	0.000892	CcSEcCtD
Vemurafenib—Dizziness—Triamcinolone—systemic lupus erythematosus	4.84e-05	0.000886	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methotrexate—systemic lupus erythematosus	4.84e-05	0.000885	CcSEcCtD
Vemurafenib—Dizziness—Methylprednisolone—systemic lupus erythematosus	4.83e-05	0.000884	CcSEcCtD
Vemurafenib—Infection—Methotrexate—systemic lupus erythematosus	4.81e-05	0.000879	CcSEcCtD
Vemurafenib—Asthenia—Betamethasone—systemic lupus erythematosus	4.77e-05	0.000872	CcSEcCtD
Vemurafenib—Asthenia—Dexamethasone—systemic lupus erythematosus	4.77e-05	0.000872	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—systemic lupus erythematosus	4.74e-05	0.000868	CcSEcCtD
Vemurafenib—Nausea—Prednisolone—systemic lupus erythematosus	4.73e-05	0.000866	CcSEcCtD
Vemurafenib—Pruritus—Betamethasone—systemic lupus erythematosus	4.7e-05	0.00086	CcSEcCtD
Vemurafenib—Pruritus—Dexamethasone—systemic lupus erythematosus	4.7e-05	0.00086	CcSEcCtD
Vemurafenib—Skin disorder—Methotrexate—systemic lupus erythematosus	4.7e-05	0.00086	CcSEcCtD
Vemurafenib—Vomiting—Triamcinolone—systemic lupus erythematosus	4.66e-05	0.000852	CcSEcCtD
Vemurafenib—Vomiting—Methylprednisolone—systemic lupus erythematosus	4.65e-05	0.00085	CcSEcCtD
Vemurafenib—Nausea—Hydrocortisone—systemic lupus erythematosus	4.62e-05	0.000845	CcSEcCtD
Vemurafenib—Rash—Triamcinolone—systemic lupus erythematosus	4.62e-05	0.000845	CcSEcCtD
Vemurafenib—Dermatitis—Triamcinolone—systemic lupus erythematosus	4.62e-05	0.000844	CcSEcCtD
Vemurafenib—Rash—Methylprednisolone—systemic lupus erythematosus	4.61e-05	0.000843	CcSEcCtD
Vemurafenib—Dermatitis—Methylprednisolone—systemic lupus erythematosus	4.6e-05	0.000842	CcSEcCtD
Vemurafenib—Headache—Triamcinolone—systemic lupus erythematosus	4.59e-05	0.00084	CcSEcCtD
Vemurafenib—Headache—Methylprednisolone—systemic lupus erythematosus	4.58e-05	0.000838	CcSEcCtD
Vemurafenib—Body temperature increased—Prednisone—systemic lupus erythematosus	4.58e-05	0.000837	CcSEcCtD
Vemurafenib—Diarrhoea—Dexamethasone—systemic lupus erythematosus	4.55e-05	0.000832	CcSEcCtD
Vemurafenib—Diarrhoea—Betamethasone—systemic lupus erythematosus	4.55e-05	0.000832	CcSEcCtD
Vemurafenib—Hypotension—Methotrexate—systemic lupus erythematosus	4.52e-05	0.000827	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	4.41e-05	0.000806	CcSEcCtD
Vemurafenib—Dizziness—Dexamethasone—systemic lupus erythematosus	4.4e-05	0.000804	CcSEcCtD
Vemurafenib—Dizziness—Betamethasone—systemic lupus erythematosus	4.4e-05	0.000804	CcSEcCtD
Vemurafenib—Nausea—Triamcinolone—systemic lupus erythematosus	4.35e-05	0.000796	CcSEcCtD
Vemurafenib—Nausea—Methylprednisolone—systemic lupus erythematosus	4.34e-05	0.000794	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisone—systemic lupus erythematosus	4.27e-05	0.00078	CcSEcCtD
Vemurafenib—Vomiting—Dexamethasone—systemic lupus erythematosus	4.23e-05	0.000773	CcSEcCtD
Vemurafenib—Vomiting—Betamethasone—systemic lupus erythematosus	4.23e-05	0.000773	CcSEcCtD
Vemurafenib—Decreased appetite—Methotrexate—systemic lupus erythematosus	4.21e-05	0.000769	CcSEcCtD
Vemurafenib—Rash—Dexamethasone—systemic lupus erythematosus	4.19e-05	0.000767	CcSEcCtD
Vemurafenib—Rash—Betamethasone—systemic lupus erythematosus	4.19e-05	0.000767	CcSEcCtD
Vemurafenib—Dermatitis—Betamethasone—systemic lupus erythematosus	4.19e-05	0.000766	CcSEcCtD
Vemurafenib—Dermatitis—Dexamethasone—systemic lupus erythematosus	4.19e-05	0.000766	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	4.18e-05	0.000764	CcSEcCtD
Vemurafenib—Fatigue—Methotrexate—systemic lupus erythematosus	4.17e-05	0.000763	CcSEcCtD
Vemurafenib—Headache—Dexamethasone—systemic lupus erythematosus	4.16e-05	0.000762	CcSEcCtD
Vemurafenib—Headache—Betamethasone—systemic lupus erythematosus	4.16e-05	0.000762	CcSEcCtD
Vemurafenib—Asthenia—Prednisone—systemic lupus erythematosus	4.15e-05	0.00076	CcSEcCtD
Vemurafenib—Pruritus—Prednisone—systemic lupus erythematosus	4.1e-05	0.000749	CcSEcCtD
Vemurafenib—Diarrhoea—Prednisone—systemic lupus erythematosus	3.96e-05	0.000725	CcSEcCtD
Vemurafenib—Nausea—Dexamethasone—systemic lupus erythematosus	3.95e-05	0.000722	CcSEcCtD
Vemurafenib—Nausea—Betamethasone—systemic lupus erythematosus	3.95e-05	0.000722	CcSEcCtD
Vemurafenib—Dizziness—Prednisone—systemic lupus erythematosus	3.83e-05	0.0007	CcSEcCtD
Vemurafenib—Body temperature increased—Methotrexate—systemic lupus erythematosus	3.82e-05	0.0007	CcSEcCtD
Vemurafenib—Vomiting—Prednisone—systemic lupus erythematosus	3.68e-05	0.000673	CcSEcCtD
Vemurafenib—Rash—Prednisone—systemic lupus erythematosus	3.65e-05	0.000668	CcSEcCtD
Vemurafenib—Dermatitis—Prednisone—systemic lupus erythematosus	3.65e-05	0.000667	CcSEcCtD
Vemurafenib—Headache—Prednisone—systemic lupus erythematosus	3.63e-05	0.000663	CcSEcCtD
Vemurafenib—Hypersensitivity—Methotrexate—systemic lupus erythematosus	3.56e-05	0.000652	CcSEcCtD
Vemurafenib—Asthenia—Methotrexate—systemic lupus erythematosus	3.47e-05	0.000635	CcSEcCtD
Vemurafenib—Nausea—Prednisone—systemic lupus erythematosus	3.44e-05	0.000629	CcSEcCtD
Vemurafenib—Pruritus—Methotrexate—systemic lupus erythematosus	3.42e-05	0.000626	CcSEcCtD
Vemurafenib—Diarrhoea—Methotrexate—systemic lupus erythematosus	3.31e-05	0.000606	CcSEcCtD
Vemurafenib—Dizziness—Methotrexate—systemic lupus erythematosus	3.2e-05	0.000585	CcSEcCtD
Vemurafenib—Vomiting—Methotrexate—systemic lupus erythematosus	3.08e-05	0.000563	CcSEcCtD
Vemurafenib—Rash—Methotrexate—systemic lupus erythematosus	3.05e-05	0.000558	CcSEcCtD
Vemurafenib—Dermatitis—Methotrexate—systemic lupus erythematosus	3.05e-05	0.000557	CcSEcCtD
Vemurafenib—Headache—Methotrexate—systemic lupus erythematosus	3.03e-05	0.000554	CcSEcCtD
Vemurafenib—Nausea—Methotrexate—systemic lupus erythematosus	2.87e-05	0.000526	CcSEcCtD
Vemurafenib—CYP3A4—Biological oxidations—RXRA—systemic lupus erythematosus	1.29e-05	0.000267	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—CDKN1A—systemic lupus erythematosus	1.28e-05	0.000266	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—F2—systemic lupus erythematosus	1.28e-05	0.000265	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—IL6—systemic lupus erythematosus	1.27e-05	0.000262	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—C3—systemic lupus erythematosus	1.26e-05	0.000261	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—IL6—systemic lupus erythematosus	1.26e-05	0.000261	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—IL6—systemic lupus erythematosus	1.25e-05	0.00026	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCL12—systemic lupus erythematosus	1.25e-05	0.000259	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CRP—systemic lupus erythematosus	1.25e-05	0.000259	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—IL6—systemic lupus erythematosus	1.25e-05	0.000259	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PTPRC—systemic lupus erythematosus	1.21e-05	0.000252	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1RN—systemic lupus erythematosus	1.21e-05	0.00025	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—PPARG—systemic lupus erythematosus	1.21e-05	0.00025	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—TLR4—systemic lupus erythematosus	1.2e-05	0.000248	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NAT2—systemic lupus erythematosus	1.18e-05	0.000245	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—IL6—systemic lupus erythematosus	1.17e-05	0.000243	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—systemic lupus erythematosus	1.17e-05	0.000243	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—IL6—systemic lupus erythematosus	1.17e-05	0.000243	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP9—systemic lupus erythematosus	1.17e-05	0.000241	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—RASGRP1—systemic lupus erythematosus	1.17e-05	0.000241	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—IL6—systemic lupus erythematosus	1.16e-05	0.000241	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—IL6—systemic lupus erythematosus	1.16e-05	0.000239	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—IL6—systemic lupus erythematosus	1.15e-05	0.000239	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-DRB1—systemic lupus erythematosus	1.15e-05	0.000238	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—IL6—systemic lupus erythematosus	1.15e-05	0.000238	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TLR9—systemic lupus erythematosus	1.13e-05	0.000235	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD40—systemic lupus erythematosus	1.13e-05	0.000234	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IFNA1—systemic lupus erythematosus	1.12e-05	0.000232	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CTLA4—systemic lupus erythematosus	1.11e-05	0.00023	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HMGB1—systemic lupus erythematosus	1.11e-05	0.00023	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IL6—systemic lupus erythematosus	1.11e-05	0.000229	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CD80—systemic lupus erythematosus	1.11e-05	0.000229	CbGpPWpGaD
Vemurafenib—BRAF—Disease—JAK1—systemic lupus erythematosus	1.1e-05	0.000228	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—P2RY12—systemic lupus erythematosus	1.1e-05	0.000227	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFNA1—systemic lupus erythematosus	1.09e-05	0.000226	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—RASGRP1—systemic lupus erythematosus	1.09e-05	0.000226	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	1.07e-05	0.000221	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL12—systemic lupus erythematosus	1.07e-05	0.000221	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—RASGRP1—systemic lupus erythematosus	1.06e-05	0.000221	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—ALB—systemic lupus erythematosus	1.06e-05	0.00022	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD79A—systemic lupus erythematosus	1.06e-05	0.00022	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD80—systemic lupus erythematosus	1.06e-05	0.00022	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TYK2—systemic lupus erythematosus	1.06e-05	0.000219	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—JUNB—systemic lupus erythematosus	1.05e-05	0.000217	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—VEGFA—systemic lupus erythematosus	1.05e-05	0.000217	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CCR5—systemic lupus erythematosus	1.04e-05	0.000216	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—systemic lupus erythematosus	1.04e-05	0.000215	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HIST2H2AC—systemic lupus erythematosus	1.04e-05	0.000215	CbGpPWpGaD
Vemurafenib—RAF1—Disease—JUNB—systemic lupus erythematosus	1.03e-05	0.000214	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PRL—systemic lupus erythematosus	1.03e-05	0.000214	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—JUNB—systemic lupus erythematosus	1.03e-05	0.000212	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—NOS3—systemic lupus erythematosus	1.02e-05	0.000211	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CSK—systemic lupus erythematosus	1.01e-05	0.000209	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—systemic lupus erythematosus	1.01e-05	0.000208	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RASGRP1—systemic lupus erythematosus	9.95e-06	0.000206	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-DQA1—systemic lupus erythematosus	9.79e-06	0.000203	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PRL—systemic lupus erythematosus	9.65e-06	0.0002	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	9.6e-06	0.000199	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PRL—systemic lupus erythematosus	9.53e-06	0.000197	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PRL—systemic lupus erythematosus	9.45e-06	0.000196	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—TYK2—systemic lupus erythematosus	9.33e-06	0.000193	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NCF2—systemic lupus erythematosus	9.23e-06	0.000191	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	9.2e-06	0.000191	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	9.18e-06	0.00019	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—LYN—systemic lupus erythematosus	9.17e-06	0.00019	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-DQB1—systemic lupus erythematosus	9.16e-06	0.00019	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	9.12e-06	0.000189	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—JAK1—systemic lupus erythematosus	9.04e-06	0.000187	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—IL2—systemic lupus erythematosus	9e-06	0.000186	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SH2B3—systemic lupus erythematosus	9e-06	0.000186	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	8.73e-06	0.000181	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL18—systemic lupus erythematosus	8.69e-06	0.00018	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD40LG—systemic lupus erythematosus	8.65e-06	0.000179	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—IL2—systemic lupus erythematosus	8.62e-06	0.000179	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CD80—systemic lupus erythematosus	8.59e-06	0.000178	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCR5—systemic lupus erythematosus	8.56e-06	0.000177	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD8A—systemic lupus erythematosus	8.56e-06	0.000177	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—JAK1—systemic lupus erythematosus	8.48e-06	0.000176	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL2RA—systemic lupus erythematosus	8.44e-06	0.000175	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CD4—systemic lupus erythematosus	8.44e-06	0.000175	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	8.39e-06	0.000174	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—C3—systemic lupus erythematosus	8.37e-06	0.000173	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP9—systemic lupus erythematosus	8.32e-06	0.000172	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—JAK1—systemic lupus erythematosus	8.26e-06	0.000171	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL6—systemic lupus erythematosus	8.14e-06	0.000169	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD4—systemic lupus erythematosus	8.1e-06	0.000168	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	8.03e-06	0.000166	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—IL6—systemic lupus erythematosus	8e-06	0.000166	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CDKN1B—systemic lupus erythematosus	7.93e-06	0.000164	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL2RA—systemic lupus erythematosus	7.92e-06	0.000164	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—EP300—systemic lupus erythematosus	7.89e-06	0.000163	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—EP300—systemic lupus erythematosus	7.74e-06	0.00016	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—JAK1—systemic lupus erythematosus	7.72e-06	0.00016	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2RA—systemic lupus erythematosus	7.71e-06	0.00016	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—VEGFA—systemic lupus erythematosus	7.65e-06	0.000158	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—C3—systemic lupus erythematosus	7.65e-06	0.000158	CbGpPWpGaD
Vemurafenib—RAF1—Disease—JAK1—systemic lupus erythematosus	7.62e-06	0.000158	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CDKN1B—systemic lupus erythematosus	7.62e-06	0.000158	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—JAK1—systemic lupus erythematosus	7.56e-06	0.000157	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—RXRA—systemic lupus erythematosus	7.53e-06	0.000156	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—VEGFA—systemic lupus erythematosus	7.47e-06	0.000155	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL12—systemic lupus erythematosus	7.38e-06	0.000153	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—F2—systemic lupus erythematosus	7.35e-06	0.000152	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—VEGFA—systemic lupus erythematosus	7.33e-06	0.000152	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CDKN1A—systemic lupus erythematosus	7.32e-06	0.000152	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCR5—systemic lupus erythematosus	7.31e-06	0.000151	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NAT2—systemic lupus erythematosus	7.29e-06	0.000151	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CRP—systemic lupus erythematosus	7.27e-06	0.000151	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TYK2—systemic lupus erythematosus	7.25e-06	0.00015	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—JUNB—systemic lupus erythematosus	7.25e-06	0.00015	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—IL6—systemic lupus erythematosus	7.24e-06	0.00015	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CCR5—systemic lupus erythematosus	7.22e-06	0.00015	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2RA—systemic lupus erythematosus	7.21e-06	0.000149	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CCR5—systemic lupus erythematosus	7.16e-06	0.000148	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—C3—systemic lupus erythematosus	7.15e-06	0.000148	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NOS3—systemic lupus erythematosus	7.12e-06	0.000147	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CDKN1A—systemic lupus erythematosus	7.03e-06	0.000146	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic lupus erythematosus	7.02e-06	0.000145	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	6.98e-06	0.000145	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TLR4—systemic lupus erythematosus	6.97e-06	0.000144	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-DRB1—systemic lupus erythematosus	6.97e-06	0.000144	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EP300—systemic lupus erythematosus	6.97e-06	0.000144	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—F2—systemic lupus erythematosus	6.89e-06	0.000143	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RASGRP1—systemic lupus erythematosus	6.88e-06	0.000143	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TGFB1—systemic lupus erythematosus	6.86e-06	0.000142	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TGFB1—systemic lupus erythematosus	6.73e-06	0.000139	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PRL—systemic lupus erythematosus	6.68e-06	0.000138	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—RXRA—systemic lupus erythematosus	6.62e-06	0.000137	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CD4—systemic lupus erythematosus	6.56e-06	0.000136	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCL2—systemic lupus erythematosus	6.55e-06	0.000136	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTGS2—systemic lupus erythematosus	6.51e-06	0.000135	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD80—systemic lupus erythematosus	6.44e-06	0.000133	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	6.42e-06	0.000133	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—systemic lupus erythematosus	6.4e-06	0.000133	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—F2—systemic lupus erythematosus	6.27e-06	0.00013	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CDKN1B—systemic lupus erythematosus	6.17e-06	0.000128	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NAT2—systemic lupus erythematosus	6.02e-06	0.000125	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CD80—systemic lupus erythematosus	6.01e-06	0.000125	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—TYK2—systemic lupus erythematosus	5.95e-06	0.000123	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD80—systemic lupus erythematosus	5.94e-06	0.000123	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD80—systemic lupus erythematosus	5.89e-06	0.000122	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	5.79e-06	0.00012	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CDKN1A—systemic lupus erythematosus	5.69e-06	0.000118	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL2—systemic lupus erythematosus	5.59e-06	0.000116	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NOS3—systemic lupus erythematosus	5.47e-06	0.000113	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TYK2—systemic lupus erythematosus	5.43e-06	0.000113	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EP300—systemic lupus erythematosus	5.41e-06	0.000112	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—JAK1—systemic lupus erythematosus	5.34e-06	0.000111	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—IL6—systemic lupus erythematosus	5.17e-06	0.000107	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NAT2—systemic lupus erythematosus	5.1e-06	0.000106	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFNG—systemic lupus erythematosus	5.09e-06	0.000105	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TYK2—systemic lupus erythematosus	5.08e-06	0.000105	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCR5—systemic lupus erythematosus	5.06e-06	0.000105	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TYK2—systemic lupus erythematosus	5.02e-06	0.000104	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2RA—systemic lupus erythematosus	4.99e-06	0.000103	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NOS3—systemic lupus erythematosus	4.98e-06	0.000103	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TYK2—systemic lupus erythematosus	4.97e-06	0.000103	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL2—systemic lupus erythematosus	4.95e-06	0.000102	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—C3—systemic lupus erythematosus	4.94e-06	0.000102	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOS3—systemic lupus erythematosus	4.92e-06	0.000102	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD4—systemic lupus erythematosus	4.91e-06	0.000102	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOS3—systemic lupus erythematosus	4.88e-06	0.000101	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PPARG—systemic lupus erythematosus	4.75e-06	9.84e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TGFB1—systemic lupus erythematosus	4.71e-06	9.75e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL2—systemic lupus erythematosus	4.64e-06	9.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CDKN1B—systemic lupus erythematosus	4.62e-06	9.57e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—systemic lupus erythematosus	4.56e-06	9.45e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	4.56e-06	9.44e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD4—systemic lupus erythematosus	4.54e-06	9.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2—systemic lupus erythematosus	4.52e-06	9.36e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—systemic lupus erythematosus	4.5e-06	9.33e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD4—systemic lupus erythematosus	4.5e-06	9.31e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—systemic lupus erythematosus	4.46e-06	9.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—F2—systemic lupus erythematosus	4.34e-06	8.99e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CDKN1B—systemic lupus erythematosus	4.32e-06	8.94e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ALB—systemic lupus erythematosus	4.27e-06	8.85e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CDKN1B—systemic lupus erythematosus	4.27e-06	8.84e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CDKN1A—systemic lupus erythematosus	4.26e-06	8.83e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CDKN1B—systemic lupus erythematosus	4.23e-06	8.76e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2—systemic lupus erythematosus	4.22e-06	8.75e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PPARG—systemic lupus erythematosus	4.18e-06	8.66e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—EP300—systemic lupus erythematosus	4.16e-06	8.63e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CD80—systemic lupus erythematosus	4.16e-06	8.62e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—NOS3—systemic lupus erythematosus	4.09e-06	8.47e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—RXRA—systemic lupus erythematosus	4.09e-06	8.47e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EP300—systemic lupus erythematosus	4.06e-06	8.4e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	4.05e-06	8.39e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—systemic lupus erythematosus	4e-06	8.28e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CDKN1A—systemic lupus erythematosus	3.98e-06	8.25e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—systemic lupus erythematosus	3.94e-06	8.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CDKN1A—systemic lupus erythematosus	3.94e-06	8.15e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NAT2—systemic lupus erythematosus	3.94e-06	8.15e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CDKN1A—systemic lupus erythematosus	3.9e-06	8.08e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL2—systemic lupus erythematosus	3.87e-06	8.01e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EP300—systemic lupus erythematosus	3.79e-06	7.85e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	3.79e-06	7.85e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—systemic lupus erythematosus	3.76e-06	7.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EP300—systemic lupus erythematosus	3.75e-06	7.76e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—systemic lupus erythematosus	3.74e-06	7.74e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EP300—systemic lupus erythematosus	3.71e-06	7.69e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	3.64e-06	7.55e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—systemic lupus erythematosus	3.62e-06	7.5e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NOS3—systemic lupus erythematosus	3.6e-06	7.45e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—systemic lupus erythematosus	3.59e-06	7.44e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—systemic lupus erythematosus	3.55e-06	7.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TYK2—systemic lupus erythematosus	3.51e-06	7.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOS3—systemic lupus erythematosus	3.45e-06	7.14e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—RXRA—systemic lupus erythematosus	3.37e-06	6.99e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—systemic lupus erythematosus	3.3e-06	6.83e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—systemic lupus erythematosus	3.29e-06	6.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—systemic lupus erythematosus	3.26e-06	6.74e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—systemic lupus erythematosus	3.23e-06	6.69e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	3.19e-06	6.6e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—EP300—systemic lupus erythematosus	3.11e-06	6.44e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1B—systemic lupus erythematosus	2.99e-06	6.19e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2—systemic lupus erythematosus	2.92e-06	6.05e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—systemic lupus erythematosus	2.91e-06	6.02e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—RXRA—systemic lupus erythematosus	2.86e-06	5.92e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—systemic lupus erythematosus	2.77e-06	5.73e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1A—systemic lupus erythematosus	2.76e-06	5.71e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—EP300—systemic lupus erythematosus	2.74e-06	5.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—systemic lupus erythematosus	2.66e-06	5.5e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	2.65e-06	5.49e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EP300—systemic lupus erythematosus	2.62e-06	5.43e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARG—systemic lupus erythematosus	2.58e-06	5.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—systemic lupus erythematosus	2.48e-06	5.15e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—systemic lupus erythematosus	2.48e-06	5.14e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—systemic lupus erythematosus	2.45e-06	5.08e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—systemic lupus erythematosus	2.43e-06	5.04e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—systemic lupus erythematosus	2.28e-06	4.72e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NOS3—systemic lupus erythematosus	2.22e-06	4.6e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—RXRA—systemic lupus erythematosus	2.21e-06	4.57e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARG—systemic lupus erythematosus	2.13e-06	4.41e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—systemic lupus erythematosus	2.03e-06	4.2e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—systemic lupus erythematosus	1.92e-06	3.97e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NOS3—systemic lupus erythematosus	1.83e-06	3.8e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARG—systemic lupus erythematosus	1.8e-06	3.74e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—systemic lupus erythematosus	1.72e-06	3.56e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—EP300—systemic lupus erythematosus	1.69e-06	3.5e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—systemic lupus erythematosus	1.68e-06	3.47e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—systemic lupus erythematosus	1.62e-06	3.36e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NOS3—systemic lupus erythematosus	1.55e-06	3.22e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—systemic lupus erythematosus	1.42e-06	2.94e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—EP300—systemic lupus erythematosus	1.39e-06	2.89e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARG—systemic lupus erythematosus	1.39e-06	2.89e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—systemic lupus erythematosus	1.25e-06	2.59e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NOS3—systemic lupus erythematosus	1.2e-06	2.48e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—EP300—systemic lupus erythematosus	1.18e-06	2.45e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—systemic lupus erythematosus	1.1e-06	2.27e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—EP300—systemic lupus erythematosus	9.11e-07	1.89e-05	CbGpPWpGaD
